{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T15:52:54Z","timestamp":1777650774915,"version":"3.51.4"},"reference-count":42,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000097","name":"National Center for Research Resources","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000097","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000133","name":"Agency for Healthcare Research and Quality","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000133","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001422","name":"American Society of Hematology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001422","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["R24 HS19455"],"award-info":[{"award-number":["R24 HS19455"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007930","name":"Institute of Clinical and Translational Sciences","doi-asserted-by":"publisher","award":["UL1 TR002345"],"award-info":[{"award-number":["UL1 TR002345"]}],"id":[{"id":"10.13039\/100007930","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["K12CA167540"],"award-info":[{"award-number":["K12CA167540"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","geriatriconcology.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Geriatric Oncology"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.jgo.2021.02.009","type":"journal-article","created":{"date-parts":[[2021,3,7]],"date-time":"2021-03-07T10:50:07Z","timestamp":1615114207000},"page":"1005-1009","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Bortezomib in first-line therapy is associated with falls in older adults with multiple myeloma"],"prefix":"10.1016","volume":"12","author":[{"given":"Kelly L.","family":"Schoenbeck","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark A.","family":"Fiala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tanya M.","family":"Wildes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.jgo.2021.02.009_bb0005","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1038\/leu.2014.23","article-title":"Improved long-term survival in multiple myeloma up to the age of 80 years","volume":"28","author":"Kristinsson","year":"2014","journal-title":"Leukemia"},{"issue":"17","key":"10.1016\/j.jgo.2021.02.009_bb0010","doi-asserted-by":"crossref","first-page":"2758","DOI":"10.1200\/JCO.2008.20.8983","article-title":"Future of cancer incidence in the United States: burdens upon an aging, changing nation","volume":"27","author":"Smith","year":"2009","journal-title":"JCO"},{"issue":"13","key":"10.1016\/j.jgo.2021.02.009_bb0015","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1182\/blood-2014-12-615187","article-title":"Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an international myeloma working group report","volume":"125","author":"Palumbo","year":"2015","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.jgo.2021.02.009_bb0020","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1111\/jgs.15715","article-title":"Geriatric assessment in older adults with multiple myeloma","volume":"67","author":"Wildes","year":"2019","journal-title":"J Am Geriatr Soc"},{"issue":"12 Suppl","key":"10.1016\/j.jgo.2021.02.009_bb0025","doi-asserted-by":"crossref","first-page":"3505","DOI":"10.1002\/cncr.23939","article-title":"Older adults and cancer treatment","volume":"113","author":"Given","year":"2008","journal-title":"Cancer"},{"issue":"20","key":"10.1016\/j.jgo.2021.02.009_bb0030","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1001\/jama.281.20.1895","article-title":"Fall-induced injuries and deaths among older adults","volume":"281","author":"Kannus","year":"1999","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.jgo.2021.02.009_bb0035","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1200\/JCO.2010.31.6695","article-title":"Association of cancer with geriatric syndromes in older medicare beneficiaries","volume":"29","author":"Mohile","year":"2011","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.jgo.2021.02.009_bb0040","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1016\/j.injury.2014.03.008","article-title":"Mortality in cancer patients after a fall-related injury: the impact of cancer spread and type","volume":"45","author":"Toomey","year":"2014","journal-title":"Injury"},{"issue":"20","key":"10.1016\/j.jgo.2021.02.009_bb0045","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1200\/JCO.2015.65.4327","article-title":"Validation of a prediction tool for chemotherapy toxicity in older adults with cancer","volume":"34","author":"Hurria","year":"2016","journal-title":"JCO."},{"issue":"25","key":"10.1016\/j.jgo.2021.02.009_bb0050","doi-asserted-by":"crossref","first-page":"3457","DOI":"10.1200\/JCO.2011.34.7625","article-title":"Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study","volume":"29","author":"Hurria","year":"2011","journal-title":"JCO"},{"issue":"3","key":"10.1016\/j.jgo.2021.02.009_bb0055","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.jgo.2016.01.007","article-title":"Association of falls with health-related quality of life (HRQOL) in older cancer survivors: a population based study","volume":"7","author":"Pandya","year":"2016","journal-title":"J Geriatr Oncol"},{"issue":"10","key":"10.1016\/j.jgo.2021.02.009_bb0060","first-page":"4459","article-title":"Falls in older adults with cancer: a systematic review of prevalence, injurious falls, and impact on cancer treatment","volume":"24","author":"Sattar","year":"2016","journal-title":"Support Care Cancer"},{"issue":"17","key":"10.1016\/j.jgo.2021.02.009_bb0065","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1200\/JCO.2011.40.7791","article-title":"Prospective study of falls and risk factors for falls in adults with advanced cancer","volume":"30","author":"Stone","year":"2012","journal-title":"JCO"},{"issue":"1","key":"10.1016\/j.jgo.2021.02.009_bb0070","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jgo.2014.10.003","article-title":"Systematic review of falls in older adults with cancer","volume":"6","author":"Wildes","year":"2015","journal-title":"J Geriatr Oncol"},{"issue":"10","key":"10.1016\/j.jgo.2021.02.009_bb0075","first-page":"3563","article-title":"Factors associated with falls in older adults with cancer: a validated model from the cancer and aging research group","volume":"26","author":"Wildes","year":"2018","journal-title":"Support Care Cancer"},{"issue":"1","key":"10.1016\/j.jgo.2021.02.009_bb0080","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1136\/bmjspcare-2017-001388","article-title":"Risk factors for falls in older patients with cancer","volume":"8","author":"Zhang","year":"2018","journal-title":"BMJ Support Palliat Care"},{"issue":"4","key":"10.1016\/j.jgo.2021.02.009_bb0085","doi-asserted-by":"crossref","first-page":"M211","DOI":"10.1093\/gerona\/50A.4.M211","article-title":"Peripheral neuropathy: a true risk factor for falls","volume":"50A","author":"Richardson","year":"1995","journal-title":"J Gerontol Ser A"},{"issue":"7","key":"10.1016\/j.jgo.2021.02.009_bb0090","first-page":"2059","article-title":"Falls and functional impairments in cancer survivors with chemotherapy-induced peripheral neuropathy (CIPN): a University of Rochester CCOP study","volume":"21","author":"Gewandter","year":"2013","journal-title":"Support Care Cancer"},{"issue":"1","key":"10.1016\/j.jgo.2021.02.009_bb0095","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jgo.2013.10.002","article-title":"Fall-related injuries in elderly cancer patients treated with neurotoxic chemotherapy: a retrospective cohort study","volume":"5","author":"Ward","year":"2014","journal-title":"J Geriatr Oncol"},{"issue":"23","key":"10.1016\/j.jgo.2021.02.009_bb0100","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1200\/JCO.2016.71.3552","article-title":"Falls, functioning, and disability among women with persistent symptoms of chemotherapy-induced peripheral neuropathy","volume":"35","author":"Winters-Stone","year":"2017","journal-title":"JCO"},{"key":"10.1016\/j.jgo.2021.02.009_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.clon.2020.03.011","article-title":"Falls and cancer","author":"Morris","year":"2020","journal-title":"Clin Oncol"},{"issue":"3","key":"10.1016\/j.jgo.2021.02.009_bb0110","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/ejh.13009","article-title":"Falls in older adults with multiple myeloma","volume":"100","author":"Wildes","year":"2018","journal-title":"Eur J Haematol"},{"issue":"12","key":"10.1016\/j.jgo.2021.02.009_bb0115","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/S0895-4356(00)00256-0","article-title":"Development of a comorbidity index using physician claims data","volume":"53","author":"Klabunde","year":"2000","journal-title":"J Clin Epidemiol"},{"issue":"18","key":"10.1016\/j.jgo.2021.02.009_bb0120","doi-asserted-by":"crossref","first-page":"4808","DOI":"10.1182\/blood-2011-04-348367","article-title":"Addition of rituximab to chemotherapy alone as first-line therapy improves overall survival in elderly patients with mantle cell lymphoma","volume":"118","author":"Griffiths","year":"2011","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.jgo.2021.02.009_bb0125","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1111\/j.1365-2141.2008.07573.x","article-title":"Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline","volume":"144","author":"Richardson","year":"2009","journal-title":"Br J Haematol"},{"issue":"19","key":"10.1016\/j.jgo.2021.02.009_bb0130","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.1200\/JCO.2005.04.7779","article-title":"Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib","volume":"24","author":"Richardson","year":"2006","journal-title":"JCO"},{"issue":"1","key":"10.1016\/j.jgo.2021.02.009_bb0135","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.jgo.2010.03.004","article-title":"Falls in men on androgen deprivation therapy for prostate cancer","volume":"1","author":"Hussain","year":"2010","journal-title":"J Geriatr Oncol"},{"issue":"1","key":"10.1016\/j.jgo.2021.02.009_bb0140","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/1471-2318-14-135","article-title":"Fall predictors in older cancer patients: a multicenter prospective study","volume":"14","author":"Vande Walle","year":"2014","journal-title":"BMC Geriatr"},{"issue":"11","key":"10.1016\/j.jgo.2021.02.009_bb0145","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.1007\/s00198-016-3667-7","article-title":"Patterns of selective serotonin reuptake inhibitor use and risk of falls and fractures in community-dwelling elderly people: the Three-City cohort","volume":"27","author":"Carri\u00e8re","year":"2016","journal-title":"Osteoporos Int"},{"issue":"4","key":"10.1016\/j.jgo.2021.02.009_bb0150","first-page":"1831","article-title":"Polypharmacy cut-points in older people with cancer: how many medications are too many?","volume":"24","author":"Turner","year":"2016","journal-title":"Support Care Cancer"},{"issue":"8","key":"10.1016\/j.jgo.2021.02.009_bb0155","first-page":"2273","article-title":"Geriatric assessment as an aide to understanding falls in older adults with cancer","volume":"23","author":"Williams","year":"2015","journal-title":"Support Care Cancer"},{"issue":"1","key":"10.1016\/j.jgo.2021.02.009_bb0160","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/1471-2318-11-45","article-title":"Patterns of comorbidity in community-dwelling older people hospitalised for fall-related injury: a cluster analysis","volume":"11","author":"Vu","year":"2011","journal-title":"BMC Geriatr"},{"issue":"6","key":"10.1016\/j.jgo.2021.02.009_bb0165","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.jgo.2015.08.006","article-title":"Measurement of gait speed in older adults to identify complications associated with frailty: a systematic review","volume":"6","author":"Pamoukdjian","year":"2015","journal-title":"J Geriatr Oncol"},{"issue":"2","key":"10.1016\/j.jgo.2021.02.009_bb0170","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/jhm.589","article-title":"Impact and recognition of cognitive impairment among hospitalized elders","volume":"5","author":"Boustani","year":"2010","journal-title":"J Hosp Med"},{"issue":"4","key":"10.1016\/j.jgo.2021.02.009_bb0175","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1177\/1559827616687263","article-title":"The influence of older adults' beliefs and attitudes on adopting fall prevention behaviors","volume":"12","author":"Stevens","year":"2017","journal-title":"Am J Lifestyle Med"},{"issue":"10068","key":"10.1016\/j.jgo.2021.02.009_bb0180","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0140-6736(16)31594-X","article-title":"Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial","volume":"389","author":"Durie","year":"2017","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.jgo.2021.02.009_bb0185","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/bjh.15261","article-title":"A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma","volume":"182","author":"O'donnell","year":"2018","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.jgo.2021.02.009_bb0190","doi-asserted-by":"crossref","DOI":"10.1097\/MLR.0b013e31815cecc3","article-title":"Measuring clinically significant Chemotherapy-related toxicities using medicare claims from cancer and leukemia group B (CALGB) trial participants","volume":"46","author":"Lamont","year":"2008","journal-title":"Med Care"},{"issue":"1","key":"10.1016\/j.jgo.2021.02.009_bb0195","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1529-8027.2010.00248.x","article-title":"Neurological monitoring reduces the incidence of bortezomib-induced peripheral neuropathy in multiple myeloma patients","volume":"15","author":"Velasco","year":"2010","journal-title":"J Peripher Nerv Syst"},{"key":"10.1016\/j.jgo.2021.02.009_bb0200","first-page":"37","article-title":"Managing treatment-related peripheral neuropathy in patients with multiple myeloma","volume":"6","author":"Grammatico","year":"2016","journal-title":"Blood Lymph Cancer"},{"issue":"4","key":"10.1016\/j.jgo.2021.02.009_bb0205","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s10286-012-0164-8","article-title":"Bortezomib-induced severe autonomic neuropathy","volume":"22","author":"Stratogianni","year":"2012","journal-title":"Clin Auton Res"},{"issue":"1","key":"10.1016\/j.jgo.2021.02.009_bb0210","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1472-684X-11-3","article-title":"Autonomic dysfunction in patients with advanced cancer; prevalence, clinical correlates and challenges in assessment","volume":"11","author":"Stone","year":"2012","journal-title":"BMC Palliat Care"}],"container-title":["Journal of Geriatric Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879406821000187?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879406821000187?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T09:53:33Z","timestamp":1761818013000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879406821000187"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":42,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["S1879406821000187"],"URL":"https:\/\/doi.org\/10.1016\/j.jgo.2021.02.009","relation":{},"ISSN":["1879-4068"],"issn-type":[{"value":"1879-4068","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bortezomib in first-line therapy is associated with falls in older adults with multiple myeloma","name":"articletitle","label":"Article Title"},{"value":"Journal of Geriatric Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgo.2021.02.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}